



DEUTSCHE BANK 39TH ANNUAL HEALTH CARE CONFERENCE

May 2014

Lundbeck



PROGRESS
IN MIND

Company disclaimer

This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions, product approvals and financial performance.

Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include interest rate and currency exchange rate fluctuations, delay or failure of development projects, production problems, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Lundbeck's products, introduction of competing products, Lundbeck's ability to successfully market both new and existing products, exposure to product liability and other lawsuits, changes in reimbursement rules and governmental laws and related interpretation thereof, and unexpected growth in costs and expenses.

Lundbeck undertakes no duty to update forward-looking statements.

Certain assumptions made by Lundbeck are required by Danish Securities Law for full disclosure of material corporate information. Some assumptions, including assumptions relating to sales associated with product that is prescribed for unapproved uses, are made taking into account past performances of other similar drugs for similar disease states or past performance of the same drug in other regions where the product is currently marketed. It is important to note that although physicians may, as part of their freedom to practice medicine in the US, prescribe approved drugs for any use they deem appropriate, including unapproved uses, at Lundbeck, promotion of unapproved uses is strictly prohibited.




Executing on Lundbeck's strategy

From "One product" company...

2009


The journey started in 2009



...To the "New Lundbeck"

2014+

Lundbeck products have business transforming potential



A new psychiatry portfolio of innovative therapies



- ★ Differentiated MoA fully recognized
- ★ Impressive and broad efficacy profile, including long-term data
- ★ Early experience from the US is positive
- ★ Short- and long-term data on tolerability is well received
- ★ *FOCUS* presented at ACNP, *CONNECT* data upcoming



- ★ Opportunity to grow the LAI market
- ★ sNDA for acute schizophrenia filed in the US
- ★ Relapse prevention data
- ★ Tolerability

Brexpiprazole in phase III clinical testing, potential US filing later in 2014

Expected main events in 2014

- ★ Launch Brintellix in the US ✓
- ★ Brexpiprazole data on first MDD study out of two at EPA in March ✓
- ★ Start the launch of Abilify Maintena in Europe ✓
- ★ Desmoteplase: Headline conclusions from DIAS-3
- ★ *CONNECT* and *CSFQ* headline conclusions on Brintellix
- ★ Brexpiprazole: FDA submission (pending data)
- ★ Selincro: HTA assessment in selected major European markets
- ★ Brintellix: Launch in Europe and International Markets
- ★ Abilify Maintena: New HCP friendly dual-chamber syringe approval

ON TRACK TO DELIVER LONG-TERM GROWTH

- New Products continue the solid momentum
- Additional products to be launched
- US psychiatry infrastructure established
- Expansion in International Markets